The global minimally invasive glaucoma surgery (MIGS) devices market was valued at $298.75 million in 2020 and is projected to reach $5,099.38 million by 2030, registering a CAGR of 35.0% from 2021 to 2030.
The aim of the glaucoma surgery is to lower eye pressure to prevent or reduce damage to the optic nerve with the use of minimally invasive glaucoma surgery devices (MIGS). MIGS devices such as stents, shunts, micro implants, and others are utilized for the treatment of patients with mild-to-moderate glaucoma. Rise in preference for MIGS devices over traditional glaucoma surgical devices has been witnessed over the years, as the former devices are safer, and effective compared to traditional devices. In addition, rise in focus of market players in the development of stents specifically for minimally invasive glaucoma surgeries that can reduce intraocular pressure (IOP) effectively supplements the market growth. Moreover, surge in prevalence of glaucoma, rise in geriatric population prone to varied ophthalmic diseases including glaucoma, and change in demographics globally fuel the growth of the market.
The minimally invasive glaucoma surgery (MIGS) devices market is segmented on the basis of surgery, target, product, end user, and region. By surgery, the market is bifurcated into glaucoma in conjunction with cataract and standalone glaucoma. By target, the market is divided into trabecular meshwork, suprachoroidal space, and others. By product, the market is classified into MIGS stents, MIGS shunts, and other. By end user, the market is categorized into eye hospitals, ophthalmology clinics, and ambulatory surgical centers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
In the recent years, Asia-Pacific witnessed rapid growth in the minimally invasive glaucoma surgery (MIGS) devices market, owing to steady increase in the prevalence of glaucoma in the Asian population. In addition, rise in the number of people suffering from primary angle-closure glaucoma in Japan, China, and South Korea supplement the market growth.
The aim of the glaucoma surgery is to lower eye pressure to prevent or reduce damage to the optic nerve with the use of minimally invasive glaucoma surgery devices (MIGS). MIGS devices such as stents, shunts, micro implants, and others are utilized for the treatment of patients with mild-to-moderate glaucoma. Rise in preference for MIGS devices over traditional glaucoma surgical devices has been witnessed over the years, as the former devices are safer, and effective compared to traditional devices. In addition, rise in focus of market players in the development of stents specifically for minimally invasive glaucoma surgeries that can reduce intraocular pressure (IOP) effectively supplements the market growth. Moreover, surge in prevalence of glaucoma, rise in geriatric population prone to varied ophthalmic diseases including glaucoma, and change in demographics globally fuel the growth of the market.
The minimally invasive glaucoma surgery (MIGS) devices market is segmented on the basis of surgery, target, product, end user, and region. By surgery, the market is bifurcated into glaucoma in conjunction with cataract and standalone glaucoma. By target, the market is divided into trabecular meshwork, suprachoroidal space, and others. By product, the market is classified into MIGS stents, MIGS shunts, and other. By end user, the market is categorized into eye hospitals, ophthalmology clinics, and ambulatory surgical centers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
In the recent years, Asia-Pacific witnessed rapid growth in the minimally invasive glaucoma surgery (MIGS) devices market, owing to steady increase in the prevalence of glaucoma in the Asian population. In addition, rise in the number of people suffering from primary angle-closure glaucoma in Japan, China, and South Korea supplement the market growth.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global minimally invasive glaucoma surgery (MIGS) devices market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the products and end users of minimally invasive glaucoma surgery (MIGS) devices used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Surgery
- Glaucoma in Conjunction with Cataract
- Standalone Glaucoma
By Target
- Trabecular Meshwork
- Suprachoroidal Space
- Others
By Product
- MIGS Stents
- MIGS Shunts
- Other
By End User
- Eye Hospitals
- Ophthalmology Clinics
- Outpatient Surgical Centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Turkey
- Saudi Arabia
- Rest of LAMEA
KEY MARKET PLAYERS
- AbbVie Inc.
- Asico LLC.
- Glaukos Corporation
- iSTAR Medical SA
- Ivantis Inc.
- Lumenis Ltd.
- Ziemer Ophthalmic Systems AG
- Novartis International AG
- Santen Pharmaceutical Co. Ltd.
- Carl Zeiss Meditec AG
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in geriatric population along with surge in prevalence of glaucoma around the world
3.5.1.2. Increase in focus of key players in the development of MIGS stents
3.5.1.3. Rise in the demand for combined glaucoma and cataract surgeries
3.5.2. Restraints
3.5.2.1. Reimbursement barriers regarding MIGS devices
3.5.2.2. Dearth of skilled professionals
3.5.3. Opportunity
3.5.3.1. Rapid transition from glaucoma medications to minimally invasive glaucoma surgeries
3.5.4. Impact analysis
3.6. COVID-19 impact analysis on the minimally invasive glaucoma surgery (MIGS) devices market
CHAPTER 4: MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY SURGERY4.1. Overview
4.1.1. Market size and forecast
4.2. GLAUCOMA IN CONJUNCTION WITH CATARACT
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. STANDALONE GLAUCOMA
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
CHAPTER 5: MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET5.1. Overview
5.1.1. Market size and forecast
5.2. TRABECULAR MESHWORK
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. SUPRACHOROIDAL SPACE
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market analysis, by country
5.4. Others
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market analysis, by country
CHAPTER 6: MINIMALLYLY INVASIVE GLAUCOMA PRODUCT (MIGS) DEVICES MARKET, BY PRODUCT6.1. Overview
6.1.1. Market size and forecast
6.2. MIGS STENTS
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market analysis, by country
6.3. MIGS SHUNTS
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market analysis, by country
6.4. OTHER (TRABECTOME/MICRO-IMPLANTS/MICRO-CATHETERS)
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market analysis, by country
CHAPTER 7: MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER7.1. Overview
7.1.1. Market size and forecast
7.2. EYE HOSPITALS
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market analysis, by country
7.3. OPHTHALMOLOGY CLINICS
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market analysis, by country
7.4. OUTPATIENT SURGICAL CENTERS
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market analysis, by country
CHAPTER 8: MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY REGION8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends, Key growth factors and opportunities
8.2.2. Market size and forecast, by country
8.2.2.1. U.S.
8.2.2.1.1. U.S. Minimally invasive glaucoma surgery devices market by surgery
8.2.2.1.2. U.S. Minimally invasive glaucoma surgery devices market by target
8.2.2.1.3. U.S. Minimally invasive glaucoma surgery devices market by product
8.2.2.1.4. U.S. Minimally invasive glaucoma surgery devices market by end user
8.2.2.2. Canada
8.2.2.2.1. Canada Minimally invasive glaucoma surgery devices market by surgery
8.2.2.2.2. Canada Minimally invasive glaucoma surgery devices market by target
8.2.2.2.3. Canada Minimally invasive glaucoma surgery devices market by product
8.2.2.2.4. Canada Minimally invasive glaucoma surgery devices market by end user
8.2.2.3. Mexico
8.2.2.3.1. Mexico Minimally invasive glaucoma surgery devices market by surgery
8.2.2.3.2. Mexico Minimally invasive glaucoma surgery devices market by target
8.2.2.3.3. Mexico Minimally invasive glaucoma surgery devices market by product
8.2.2.3.4. Mexico Minimally invasive glaucoma surgery devices market by end user
8.2.3. Market size and forecast, by surgery
8.2.4. Market size and forecast, by target
8.2.5. Market size and forecast, by product
8.2.6. Market size and forecast, by end user
8.3. Europe
8.3.1. Key market trends, key growth factors and opportunities
8.3.2. Market size and forecast
8.3.2.1. Germany
8.3.2.1.1. Germany Minimally invasive glaucoma surgery devices market by surgery
8.3.2.1.2. Germany Minimally invasive glaucoma surgery devices market by target
8.3.2.1.3. Germany Minimally invasive glaucoma surgery devices market by product
8.3.2.1.4. Germany Minimally invasive glaucoma surgery devices market by end user
8.3.2.2. France
8.3.2.2.1. France Minimally invasive glaucoma surgery devices market by surgery
8.3.2.2.2. France Minimally invasive glaucoma surgery devices market by target
8.3.2.2.3. France Minimally invasive glaucoma surgery devices market by product
8.3.2.2.4. France Minimally invasive glaucoma surgery devices market by end user
8.3.2.3. Italy
8.3.2.3.1. Italy Minimally invasive glaucoma surgery devices market by surgery
8.3.2.3.2. Italy Minimally invasive glaucoma surgery devices market by target
8.3.2.3.3. Italy Minimally invasive glaucoma surgery devices market by product
8.3.2.3.4. Italy Minimally invasive glaucoma surgery devices market by end user
8.3.2.4. Spain
8.3.2.4.1. Spain Minimally invasive glaucoma surgery devices market by surgery
8.3.2.4.2. Spain Minimally invasive glaucoma surgery devices market by target
8.3.2.4.3. Spain Minimally invasive glaucoma surgery devices market by product
8.3.2.4.4. Spain Minimally invasive glaucoma surgery devices market by end user
8.3.2.5. UK
8.3.2.5.1. UK Minimally invasive glaucoma surgery devices market by surgery
8.3.2.5.2. UK Minimally invasive glaucoma surgery devices market by target
8.3.2.5.3. UK Minimally invasive glaucoma surgery devices market by product
8.3.2.5.4. UK Minimally invasive glaucoma surgery devices market by end user
8.3.2.6. Rest of Europe
8.3.2.6.1. Rest of Europe Minimally invasive glaucoma surgery devices market by surgery
8.3.2.6.2. Rest of Europe Minimally invasive glaucoma surgery devices market by target
8.3.2.6.3. Rest of Europe Minimally invasive glaucoma surgery devices market by product
8.3.2.6.4. Rest of Europe Minimally invasive glaucoma surgery devices market by end user
8.3.3. Market size and forecast, by surgery
8.3.4. Market size and forecast, by target
8.3.5. Market size and forecast, by product
8.3.6. Market size and forecast, by end user
8.4. Asia-Pacific
8.4.1. Key market trends, key growth factors and opportunities
8.4.2. Market size and forecast, by country
8.4.2.1. Japan
8.4.2.1.1. Japan Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.1.2. Japan Minimally invasive glaucoma surgery devices market, by target
8.4.2.1.3. Japan Minimally invasive glaucoma surgery devices market, by product
8.4.2.1.4. Japan Minimally invasive glaucoma surgery devices market, by end user
8.4.2.2. China
8.4.2.2.1. China Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.2.2. China Minimally invasive glaucoma surgery devices market, by target
8.4.2.2.3. China Minimally invasive glaucoma surgery devices market, by product
8.4.2.2.4. China Minimally invasive glaucoma surgery devices market, by end user
8.4.2.3. India
8.4.2.3.1. India Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.3.2. India Minimally invasive glaucoma surgery devices market, by target
8.4.2.3.3. India Minimally invasive glaucoma surgery devices market, by product
8.4.2.3.4. India Minimally invasive glaucoma surgery devices market, by end user
8.4.2.4. Australia
8.4.2.4.1. Australia Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.4.2. Australia Minimally invasive glaucoma surgery devices market, by target
8.4.2.4.3. Australia Minimally invasive glaucoma surgery devices market, by product
8.4.2.4.4. Australia Minimally invasive glaucoma surgery devices market, by end user
8.4.2.5. South Korea
8.4.2.5.1. South Korea Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.5.2. South Korea Minimally invasive glaucoma surgery devices market, by target
8.4.2.5.3. South Korea Minimally invasive glaucoma surgery devices market, by product
8.4.2.5.4. South Korea Minimally invasive glaucoma surgery devices market, by end user
8.4.2.6. Rest of Asia-Pacific
8.4.2.6.1. Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.4.2.6.2. Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by target
8.4.2.6.3. Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by product
8.4.2.6.4. Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.4.3. Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.4.4. Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by target
8.4.5. Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by product
8.4.6. Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5. LAMEA
8.5.1. Key market trends, Key growth factors and opportunities
8.5.2. Market size and forecast, by country
8.5.2.1. Brazil
8.5.2.1.1. Brazil Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.1.2. Brazil Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.1.3. Brazil Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.1.4. Brazil Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.2. Turkey
8.5.2.2.1. Turkey Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.2.2. Turkey Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.2.3. Turkey Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.2.4. Turkey Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.3. Saudi Arabia
8.5.2.3.1. Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.3.2. Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.3.3. Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.3.4. Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.4. South Africa
8.5.2.4.1. South Africa Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.4.2. South Africa Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.4.3. South Africa Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.4.4. South Africa Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.5. Rest of LAMEA
8.5.2.5.1. Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.5.2. Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.5.3. Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.5.4. Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.3. LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.4. LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.5. LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.6. LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by end user
CHAPTER 9: COMPANY PROFILES9.1. ABBVIE INC. (ALLERGAN)
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments
9.2. ASICO LLC
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.3. GLAUKOS CORPORATION
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. ISTAR MEDICAL SA
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Key strategic moves and developments
9.5. IVANTIS INC.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Key strategic moves and developments
9.6. LUMENIS LTD.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Key strategic moves and developments
9.7. ZIEMER OPHTHALMIC SYSTEMS AG
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.8. NOVARTIS INTERNATIONAL AG (ALCON INC.)
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.9. SANTEN PHARMACEUTICAL CO. LTD.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.10. CARL ZEISS MEDITEC AG
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments
List of Tables
TABLE 01. MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 02. MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR GLAUCOMA IN CONJUNCTION WITH CATARACT, BY REGION, 2020-2030 ($MILLION)
TABLE 03. MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR STANDALONE GLAUCOMA, BY REGION, 2020-2030 ($MILLION)
TABLE 04. MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 05. MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR TRABECULAR MESHWORK, BY REGION, 2020-2030 ($MILLION)
TABLE 06. MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR SUPRACHOROIDAL SPACE, BY REGION, 2020-2030 ($MILLION)
TABLE 07. MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER TARGET, BY REGION, 2020-2030 ($MILLION)
TABLE 08. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 09. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS STENTS, BY REGION, 2020-2030 ($MILLION)
TABLE 10. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS SHUNTS, BY REGION, 2020-2030 ($MILLION)
TABLE 11. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER, BY REGION, 2020-2030 ($MILLION)
TABLE 12. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 13. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR EYE HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 14. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OPHTHALMOLOGY CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 15. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OUTPATIENT SURGICAL CENTERS, BY REGION, 2020-2030 ($MILLION)
TABLE 16. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY REGION ($MILLION), 2020-2030
TABLE 17. NORTH AMERICA: MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY COUNTRY ($MILLION), 2020-2030
TABLE 18. U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 19. U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 20. U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 21. U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 22. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 23. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 24. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 26. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 27. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 28. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 29. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 30. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY ($MILLION), 2020-2030
TABLE 31. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET ($MILLION), 2020-2030
TABLE 32. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT ($MILLION), 2020-2030
TABLE 33. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER ($MILLION), 2020-2030
TABLE 34. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY COUNTRY ($MILLION), 2020-2030
TABLE 35. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 36. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 37. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 38. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 39. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 40. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 41. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 42. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 44. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 45. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 46. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 47. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 48. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2021-2028 ($MILLION)
TABLE 49. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2021-2028 ($MILLION)
TABLE 50. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2021-2028 ($MILLION)
TABLE 51. UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 52. UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 53. UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 54. UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 55. REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 56. REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 57. REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 58. REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY ($MILLION), 2020-2030
TABLE 60. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET ($MILLION), 2020-2030
TABLE 61. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT ($MILLION), 2020-2030
TABLE 62. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER ($MILLION), 2020-2030
TABLE 63. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 64. JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 65. JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 66. JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 67. JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 68. CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 69. CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 70. CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 71. CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72. INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 73. INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 74. INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 75. INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 76. AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2021-2028 ($MILLION)
TABLE 77. AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 78. AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 79. AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 80. SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 81. SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 82. SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 83. SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY, 2020-2030 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET, 2020-2030 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER, 2020-2030 ($MILLION)
TABLE 88. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY, 2020-2030 ($MILLION)
TABLE 89. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET, 2020-2030 ($MILLION)
TABLE 90. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 91. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER, 2020-2030 ($MILLION)
TABLE 92. LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY COUNTRY ($MILLION), 2020-2030
TABLE 93. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 94. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 95. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 96. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 97. TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 98. TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 99. TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 100. TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 101. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 102. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 103. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 104. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 105. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 106. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 107. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 108. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER($MILLION), 2020-2030
TABLE 109. REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 110. REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 111. REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT($MILLION), 2020-2030
TABLE 112. REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 113. LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY, 2020-2030 ($MILLION)
TABLE 114. LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET, 2020-2030 ($MILLION)
TABLE 115. LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 116. LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER, 2020-2030 ($MILLION)
TABLE 117. ABBVIE: COMPANY SNAPSHOT
TABLE 118. ABBVIE: OPERATING SEGMENTS
TABLE 119. ABBVIE: PRODUCT PORTFOLIO
TABLE 120. ASICO: COMPANY SNAPSHOT
TABLE 121. ASICO: OPERATING SEGMENTS
TABLE 122. ASICO: PRODUCT PORTFOLIO
TABLE 123. GLAUKOS: COMPANY SNAPSHOT
TABLE 124. GLAUKOS: OPERATING SEGMENTS
TABLE 125. GLAUKOS: PRODUCT PORTFOLIO
TABLE 126. ISTAR: COMPANY SNAPSHOT
TABLE 127. ISTAR: OPERATING SEGMENTS
TABLE 128. ISTAR: PRODUCT PORTFOLIO
TABLE 129. IVANTIS: COMPANY SNAPSHOT
TABLE 130. IVANTIS: OPERATING SEGMENTS
TABLE 131. IVANTIS: PRODUCT PORTFOLIO
TABLE 132. LUMENIS: COMPANY SNAPSHOT
TABLE 133. LUMENIS: OPERATING SEGMENTS
TABLE 134. LUMENIS: PRODUCT PORTFOLIO
TABLE 135. ZIEMER: COMPANY SNAPSHOT
TABLE 136. ZIEMER: OPERATING SEGMENTS
TABLE 137. ZIEMER: PRODUCT PORTFOLIO
TABLE 138. NOVARTIS: COMPANY SNAPSHOT
TABLE 139. NOVARTIS: OPERATING SEGMENTS
TABLE 140. NOVARTIS: PRODUCT PORTFOLIO
TABLE 141. SANTEN: COMPANY SNAPSHOT
TABLE 142. SANTEN: OPERATING SEGMENTS
TABLE 143. SANTEN: PRODUCT PORTFOLIO
TABLE 144. ZEISS: COMPANY SNAPSHOT
TABLE 145. ZEISS: OPERATING SEGMENTS
TABLE 146. ZEISS: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. SEGMENTATION OF MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. HIGH INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR GLAUCOMA IN CONJUNCTION WITH CATARACT, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR STANDALONE GLAUCOMA, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR TRABECULAR MESHWORK, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR SUPRACHOROIDAL SPACE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER TARGET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS STENTS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS SHUNTS BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF GUINEA PIGS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR EYE HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OPHTHALMOLOGY CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23. COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OUTPATIENT SURGICAL CENTERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24. ABBVIE: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26. GLAUKOS: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. GLAUKOS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28. NOVARTIS: NET SALES, 2018-2020, ($MILLION)
FIGURE 29. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31. SANTEN: NET SALES, 2018-2020, ($MILLION)
FIGURE 32. ZEISS: REVENUE, 2018-2020 ($MILLION)
FIGURE 33. ZEISS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34. ZEISS: REVENUE SHARE BY REGION, 2020 (%)
Companies Mentioned
- AbbVie Inc.
- Asico LLC.
- Glaukos Corporation
- iSTAR Medical SA
- Ivantis Inc.
- Lumenis Ltd.
- Ziemer Ophthalmic Systems AG
- Novartis International AG
- Santen Pharmaceutical Co. Ltd.
- Carl Zeiss Meditec AG.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 226 |
| Published | August 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 253.62 million |
| Forecasted Market Value ( USD | $ 5099.38 million |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
